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ABSTRACT 
The purpose of this review is to provide a comprehensive approach for assessing the upper extremity (UE) 
after stroke.  First, common upper extremity impairments and how to assess them are briefly discussed.  While 
multiple UE impairments are typically present after stroke, the severity of one impairment, paresis, is the primary 
determinant of UE functional loss.  Second, UE function is operationally defined and a number of clinical measures are 
discussed.  It is important to consider how impairment and loss of function affect UE activity outside of the clinical 
environment.  Thus, this review also identifies accelerometry as an objective method for assessing UE activity in daily 
life.  Finally, the role that each of these levels of assessment should play in clinical decision making is discussed in order 






ASSESSMENT OF UPPER EXTREMITY IMPAIRMENTS POST STROKE  
Common upper extremity (UE) impairments after stroke include:  paresis, loss of fractionated movement, 
abnormal muscle tone and/or changes in somatosensation.  These impairments are a result of direct damage to the 
primary motor cortex, the primary somatosensory cortex, secondary sensorimotor cortical areas, subcortical 
structures, and/or the corticospinal tract.  The evaluation determines the presence and severity of each impairment 
and how the impairments are contributing to loss of movement and function.  Systematic, routine measurement of 
impairments are critical for clinical decision making 1-3.  Each impairment is discussed below and common methods 
used for assessment are provided in Table 1.  
Paresis 
The most common motor impairment seen after stroke is paresis4.  Paresis is a decreased ability to volitionally 
activate motor units 5-10 and is caused by damage to the corticospinal system (the primary motor cortex, non-primary 
cortical motor areas, corticospinal tract).  Poor or absent volitional control of motor units means that muscles and sets 
of muscles cannot be activated in a timely, coordinated manner nor activated with sufficient force 11-21.  Clinically, 
paresis appears as weakness and results in slower, less accurate, and less efficient movements compared to those in 
neurologically-intact individuals 22, 23.  A stroke will cause paresis on one side of the body, contralateral to the lesioned 
brain, i.e. hemiparesis.  Individuals with mild paresis will have movements that appear to be normal or near normal, 
while those with severe paresis, or plegia, may not be able to move at all.  Contrary to common perception, it has been 
shown that the severity of paresis is similar across all segments of the UE and is not worse at the distal segments 
compared to proximal ones 24, 25.   
Loss of Fractionated Movement 
 Fractionation of movement is the ability to voluntarily move one segment independently of other segments.   
Like paresis, fractionated movement deficits may be present after stroke damages the corticospinal system. The 
corticospinal system is the primary neural substrate for the enormous repertoire of complex, skilled movements 
humans can perform with the upper extremities 26, 27.  Stroke-induced damage results in a decreased ability to 
selectively activate muscles 16, 21, 28; this is the same phenomenon as the “associated reactions” and “abnormal 
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synergies” commonly described after stroke 29. Loss of ability to fractionate movement is also not specific to distal 
segments but has been demonstrated across all segments of the UE 30.  For example, inadvertent flexion of the 
shoulder, wrist, and/or fingers may occur during instructed or voluntary flexion of the elbow.  Because fractionation of 
movement is essential for skilled UE motor control 26, a reduced ability to fractionate movement can limit function.   
Abnormal Muscle Tone 
 Muscle tone is the resistance of muscle to passive elongation or stretch 31. There is a broad range of normal 
muscle tone seen in healthy individuals.  Abnormal muscle tone is often separated into two major categories: 
hypotonicity and hypertonicity.  Hypotonicity is reduced muscle tone resulting from a decreased or absent neural drive 
to the muscle 32. It is often seen acutely after stroke as a result of damage to the corticospinal neurons, appearing as a 
decreased resistance to passive movement and a decreased or absent stretch reflex response 33.  Hypertonicity, also 
referred to as spasticity or hyperreflexia, is increased muscle tone resulting from a loss of inhibition to the spinal cord 
as a result of damage to the corticospinal tract.  Clinically, hypertonicity can be seen as an increased resistance to 
passive movement (spasticity = the velocity-dependent resistance) and an increased stretch reflex response 33. In this 
case the limb may be harder to move and range of motion may be limited.  Typically after stroke, hypotonicity is seen 
first, and then hypertonicity develops during the first few weeks and months.    
Loss of Somatosensation 
 If stroke damages the ascending somatosensory pathways and/or the somatosensory cortical areas, then 
individuals will have a reduction or loss of somatosensation.  As a consequence of this loss, the nervous system has less 
ability to monitor and correct movement.  The clinical picture of somatosensory loss due to stroke is global, generally 
affecting an entire side of the body.  There are numerous impairment-based measures that exist to assess impairments 
of somatosensory modalities (light touch, joint position sense, vibration, etc.).  The modality most often tested by 
occupational and physical therapists is light touch 34.  People post-stroke who have somatosensory loss in one 
modality, such as light touch, typically have somatosensory loss in other modalities, such as proprioception 35.  It is 
therefore reasonable in people post-stroke to do a quick screen of one somatosensory modality, light touch, on only 
one or two places on the affected limb.   
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CONTRIBUTIONS OF UPPER EXTREMITY IMPAIRMENTS TO LOSS OF FUNCTION POST STROKE  
Although each of the impairments listed above can occur in isolation, more often they exist in combinations.  
This is because the stroke-induced impairments are either caused by damage to the same neurological structures (e.g. 
paresis, loss of fractionated movement, and abnormal tone due to damage to the corticospinal system) or caused by 
damage to adjacent structures (e.g. paresis and loss of somatosensation due to damage to the primary motor cortex 
and its neighbor, the primary somatosensory cortex).  Thus, the severity of impairments is generally similar.  In the UE, 
the severity of paresis is highly correlated with the ability to make fractionated movement 30.  Similarly, the degree of 
spasticity, or abnormal muscle tone matches reasonably well to the severity of paresis 30.  People with more severe 
paresis and hypertonicity have less ability to fractionate movement, and people with more mild paresis and minimal 
hypertonicity can make well-fractionated movements.  While there are some cases of severe paresis (plegia) and 
hypotonicity (flaccidity), these are less commonly seen than cases with severe paresis and severe hypertonicity 
(spasticity).   
An essential issue in the assessment of the UE post stroke is how the presence of various impairments 
contributes to loss of UE function.  Here, we use the term function to indicate the capacity to perform activities with 
the UE.  Our laboratory has studied this issue in multiple samples over the past 6 years.  Rather surprisingly, our results 
are remarkably consistent and show that paresis is the biggest contributor to loss of UE function post stroke 24, 25, 30, 36, 
37.  Figure 1 is a schematic representation of these data.  Three important points are illustrated in the figure.  First, at 
nearly all time points post stroke, the severity of paresis can explain the majority of variance in UE function (Figure 1A).  
While other impairments were related to function, they were not as strongly related and did not explain any additional 
variance, beyond that accounted for by paresis.  This finding makes intuitive sense – if segments of the limb cannot 
move or move much, then function will be absent or poor.  Second, loss of UE function stems from paresis across the 
limb, and not paresis at just a few segments (Figure 1B).  The whole limb is needed for function 38.  In order to interact 
with objects in the environment, the proximal segments transport and rotate the hand.  This positions the hand so that 
the more distal segments can then contact and interact with objects.  And third, paresis a few weeks, but not a few 
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days after stroke can predict later UE function (Figure 1C).  This third finding illustrates the importance of both initial 
severity and rate of change of severity as prognostic indicators of eventual motor function 39 (see later discussion of 
prognosis in this paper).  A few days after stroke, measurements indicate the initial severity of paresis, but not the rate 
of change.  By 3 weeks post-stroke, measurements reflect both.  In sum, paresis is the most important impairment 
causing UE functional loss.  It is paresis across the entire limb that leads to decreased UE function, and the severity of 
paresis at 3 or more weeks post-stroke that is the strongest indicator of present and eventual UE function.              
  
ASSESSMENT OF UPPER EXTREMITY FUNCTION IN CLINIC/LABORATORY  
Restoring functional use of the UE is a key goal of people who experience a stroke.  Evaluation of the affected 
UE examines two key factors: 1) identification of the impairments limiting normal movement (discussed above), and 2) 
the initial level of activity limitations and participation restrictions arising from these impairments.  Measurements at 
the activity and participation levels are important in order to address complex issues such as quality of life  40.  
Outcome assessments at the activity and participation levels are necessary for determining if the selected 
rehabilitation intervention results in changes that are important to the daily life of individuals living with stroke.  
A variety of measures available for assessing UE function  
Numerous measures are readily available to clinicians for the evaluation of UE function post-stroke.  Many of 
these measures have been thoroughly evaluated for reliability and validity at multiple time points post stroke.  The 
measures can be generally divided into two categories: 1) performance measures, where the clinician rates or times a 
series of UE actions that are performed by the patient, or self-report measures, where the clinician asks a series of 
questions about UE actions that are answered verbally by the patient or by proxy.   The most frequently cited UE 
performance measures include the Action Research Arm Test (ARAT), Box and Blocks Test (BB), Chedoke Arm and Hand 
Activity Inventory (CAHAI), Jebsen-Taylor Hand Function Test (JTT), Nine-Hole Peg Test, and the Wolf Motor Function 
Test (WMFT).  The most frequently cited self-report measures include the Stroke Impact Scale (SIS) and the Motor 
Activity Log (MAL).  There is no consensus on which measure to choose for a particular person with stroke.  While 
there is no single measure that encapsulates the entire range of activities performed by the UE 41, a recent review 
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suggests that the ARAT and the BB test have the strongest clinical utility 42.  Once a measure is selected, the same 
measure should be administered at evaluation, interim and discharge evaluations, in order to document progress or 
lack thereof.  Tools to evaluate UE function are described briefly below; a summary of common psychometric 
properties and further details about each test are provided in Table 2.   
Performance Measures 
Action Research Arm Test (ARAT): Developed for patients with hemiparesis, the ARAT is a criterion-rated assessment of 
UE activity limitations 43-53.  The ARAT includes 19 items divided into four subscales: grasp, grip, pinch, and gross 
movement.  The items within each subtest are ordered based on a 4-point ordinal scale ranging from 0 to 3 where 3 
represents normal performance on each item.  The items are arranged in a hierarchy, permitting skipping some items if 
the person is unable to do an earlier item or performs an earlier item normally.  A score of 57 indicates normal 
performance.   
Box and Block Test (BB): The Box and Block test is a quick and easy to administer assessment designed to quantify UE 
activity limitations by a person’s ability to grasp, transport, and release small blocks 53-56.  Individuals are asked to move 
as many one-inch blocks across the center of the test box in one minute.  Performance is determined by the number of 
blocks moved in one minute.  Times are compared to established norms, with better performance indicated by a 
higher number of blocks moved. 
Chedoke Arm and Hand Activity Inventory (CAHAI): The CAHAI is a functional assessment used to determine how much 
the arm and hand have recovered after stroke 57-60.  The original version of the assessment is comprised of 13 items 
that require the use of both arms.  Each activity is rated on a 7-point quantitative scale ranging from 1= total assistance 
and the weak limb performs less than 25% of the task to 7= total independence.  Higher scores indicate a higher level 
of functional independence.  Three shortened versions of the test exist, the CAHAI-9, CAHAI-8 and CAHAI-7, if time to 
complete the assessment is a concern. 
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Jebsen-Taylor Hand Function Test: The Jebsen-Taylor Hand Function Test was developed to assess the use of the UE in 
everyday tasks 61.  There are seven tasks that are tested: writing a sentence, card turning, lifting small objects, 
simulated feeding, stacking checkers, and picking up light and heavy cans.  Each task is timed, and better performance 
is indicated by faster times.  Age- and gender-based normative values on each test are available for comparison.   
Nine-Hole Peg Test: The Nine-Hole Peg test is a brief measure used to quantify hand dexterity 56, 62-65.  Performance is 
quantified as the time taken to place and then remove the pegs, one at a time.  Times are compared to established 
norms, with better performance indicated by faster times.  Individuals must have some degree of volitional hand 
movement for this test to be a useful tool. 
Wolf Motor Function Test (WMFT): The WMFT is comprised of 15 tasks to evaluate UE impairments and activity 
limitations 45, 46, 48, 66-72.  Items 1-6 are timed joint-segment movements whereas items 7-15 are timed integrative 
functional movements.  The person is given a time on each item and a Functional Ability Score (FAS) on a 6-point scale 
ranging from 0 = unable to complete the task to 5 = completes the task with normal movement.  For the timed scored, 
better performance is indicated by faster times.  For the Functional Ability Score (FAS), better performance is indicated 
by higher scores, usually represented as an average of the individual item scores. 
Self-Report Measures 
Motor Activity Log (MAL): The MAL is a structured interview used to assess real-world UE activity 46, 50, 73-75.  An 
individual is asked to rate his/her performance on how much and how well the affected UE is used during a variety of 
activities typically completed in daily life.  Subscores can be derived from the Quality of Movement (QOM) scale and 
the Amount of Use (AOU) scale.  Each scale is rated on a scale of 0 – 5 where 0= “the weaker arm was not used at all 
for that activity” on the QOM scale and “did not use my weaker arm” on the AOU scale and 5= “the ability to use the 
weaker arm for that activity was as good as before the stroke” on the QOM and “used my weaker arm as often as 
before the stroke” on the AOU scale.  Scores on each scale are calculated as the mean of the scored items attempted 
with the affected arm.  Averages closer to 5 indicate better quality of movement and more use of the affected 
arm/hand.  There are two versions of the assessment; 1) MAL-28 and the shorter 2) MAL-14. 
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Stroke Impact Scale: The Stroke Impact Scale (SIS), is a stroke-specific, comprehensive health questionnaire with 
subscales in eight domains: Strength, Hand function, ADL/IADL, Mobility, Communication, Emotion, Memory and 
Thinking, & Participation/Role function 76-83.  The individual uses a 5-point Likert scale to rate his/her ability on each 
item.  Questions can be administered in a face-to-face interview format, over the telephone, or via the mail.  The 
subscales of Hand Function and ADL/IADL are most relevant for measurement of UE function.  Scores for each subscale 
range from 0 – 100, with normal self-reported function indicated by a score of 100.   
Relationships between measures at different time points post-stroke 
 Scores for many of these measures are highly inter-related, and remain so across various times post stroke.  
For example, the ARAT and the WMFT have been shown to be strongly correlated with each other at 14 days, 1, 3 , and 
6 months post-stroke 84.  Similarly, the ARAT, Jebsen-Taylor Test of Hand Function, 9-Hole Peg Test, and the Stroke 
Impact Scale – Hand Function subscale have been shown to have moderate to strong correlations at 1 month, 3 
months and 6 months post-stroke 85.  Relationships between these measures and others are provided in the fourth 
column in Table 2.  The strength and consistency of these correlations suggest that the measures quantify the same 
underlying construct, i.e. UE function, and that any one of them would be appropriate for clinical use. The decision to 
use one measure vs. another can therefore be made based on additional factors.   
Deciding which measures to use 
Since measures of UE function are highly inter-related, there is a great deal of freedom when selecting a 
measure for use with a specific individual.    Some therapists may use more than one measure, with one assessment 
intended to quickly quantify change (e.g. BB) and another measure intended to determine which UE movements (e.g. 
ARAT or WMFT) or which self-reported functional problems (e.g. MAL, SIS) need to be addressed during treatment. 
Three key questions influence the selection process.  Is the necessary equipment available?  Is specific training needed 
prior to administration? How much time does it take to administer? 
Equipment: Many of the described measures are pre-made test kits that can be purchased from reputable 
rehabilitation suppliers.  These test kits can range in price from approximately $50 up to several hundred dollars.  Both 
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the ARAT and the WMFT test kits can be built relatively economically based on descriptions in published articles or 
manuals available on the internet.  A good source for information about the tools and what each tool looks like is 
http://www.medicine.mcgill.ca/strokengine-assess/, a web-site sponsored by the Canadian Stroke Network.  
Availability of measures will vary from facility to facility.  For instance one facility may have the Jebsen-Taylor test 
while another facility may own the ARAT.  Because these measures are similar assessments of UE function, then 
choosing the test that is readily available at one’s workplace is a logical basis for test selection.   
Training: Often measures require that the administering clinician take part in a formalized training program in 
order to be certified to use the measure.  Each of the performance assessments discussed in this manuscript do not 
require additional training in order to perform them.  Some assessments, like the CAHAI provide training videos for a 
nominal fee (available online).  For other assessments, like the ARAT, there is are published instructions available that 
can be followed to ensure stable performance 86.  For most of the measures discussed here, carefully reading the 
instruction manual and practicing administration of the test will result in the measure being administered correctly.   
Time: The amount of time required to administer a measure will strongly influence whether or not it is 
selected for use in routine clinical practice.  Measures that take a shorter amount of time are more likely to be used.  
The second column in Table 2 provides an estimate of the time needed to administer each of the measures.  Note that 
it usually takes longer to administer any measure when one first starts using it.  As familiarity with the items and 
instructions increases, the time to administer the measure usually decreases.  Clinical facilities often prescribe the 
amount of time available for an evaluation.  While it is compelling to always choose the shortest measures (e.g. Box 
and Block or Nine-Hole-Peg tests), the longer measures often yield additional valuable information.  The short 
measures require performance of only one action.  The longer measures (e.g. ARAT and WMFT) evaluate performance 
on more actions.   In addition to the total score on the longer measures, observing the person with stroke interact with 
a variety of objects during administration of the longer measures will allow the treating clinician to see exactly which 
components of movement (e.g. types of grasps) and how (e.g. with large objects, cannot extend fingers sufficiently) 
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movement components are affected.  These observations can facilitate treatment planning, providing information on 
how to structure movement practice.   
  
ASSESSMENT OF UPPER EXTREMITY USE OUTSIDE THE CLINIC/LABORATORY  
Assessment of the affected UE in the clinic or laboratory includes measures of impairments, measures of 
performance, and self-report questionnaires.  Outside the clinic however, direct observation of impairment and 
performance is costly and impractical, leaving self-report measures as one of the only options.   Although self-report 
measures are often selected due to ease of administration, they are: 1) affected by comprehension, memory recall, 
and motivation 87, 88; 2) unreliable when used with persons who have cognitive deficits in memory and attention, as 
commonly experienced by persons with stroke 89; and 3) at best are moderately correlated with direct methods of 
activity measurement 90.  Furthermore, improvement on measures of function following rehabilitation has been shown 
to lack association with increased UE use at home 91.  Because improvement in daily function at home is the goal of 
rehabilitation, it is important that objective assessment tools be used to measure UE use during real-world activity 
outside of the clinic.  One such tool is the accelerometer. 
How accelerometers measure upper extremity use 
Accelerometers measure movement in terms of acceleration. Acceleration is the change in speed with respect 
to time, and is measured in gravitational acceleration units (g; 1 g=9.8 m/s²).  This is done by converting mechanical 
motion into electrical signals, often via piezoelectric sensors.  The sensors are contained within a device which is 
similar in size to a wristwatch (Figure 2A) and can be comfortably worn on the wrist 92.  The electrical signal is 
converted to a digital signal called an activity count, quantifying how much movement occurred during a specific time 
period, called an epoch 93.  The epoch is chosen by the clinician, and can be as short as a second or as long as a few 
minutes (e.g. the length of a specific activity).  One way to measure UE use is to sum activity counts per epoch as a 
measure of intensity of UE use.  Another way to measure UE use is to choose a small epoch, such as one second, and 
determine if movement occurred during that epoch. This is done by “filtering” activity counts:  if an activity count 
occurred during a one-second epoch, then movement occurred during the epoch; if an activity count did not occur 
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during the epoch, then movement did not occur during the epoch 94.  In this way, epochs where the UE was used can 
be summed to determine the amount of UE use during a given time period, such as hours in a day.  Percentage of UE 
use that occurred during the wearing time can also be determined.  Epoch selection, filtering, and calculation of UE use 
can often be done with the software program that comes with the accelerometers.  Figure 2B shows an example of 
what UE accelerometer data look like during a 1½ hour wearing time.       
Reliability and validity of accelerometer measurement 
For accelerometers to be useful, they must be reliable and valid.  Studies have shown that accelerometer 
activity counts are consistent for the same activity at different time points when the same accelerometer unit is used, 
i.e. intra-rater reliability has been established 95.  Activity counts are also consistent for the same activity when 
different accelerometer units are used, i.e. inter-rater reliability has been established 95, 96.  Furthermore, strong 
correlations between UE accelerometer counts at separate time points indicate good test-retest reliability 97, 98. 
  It is well documented that accelerometry is an objective measure of UE use, i.e. construct validity has been 
established.  Studies show 88% agreement between UE accelerometry and observed movement by an observer, as 
well as a very strong correlation (r = 0.93) between UE accelerometry and duration of movement.  Accelerometry is 
also able to distinguish UE use between people with and without stroke and between use of the affected and 
unaffected limbs of people with stroke 99, 100.  Moreover, accelerometry is sensitive to change, demonstrating increases 
in activity counts following therapeutic intervention 101-103. 
There is also ample agreement between accelerometry and accepted, standardized measures of activity, i.e. 
convergent validity has been established.  Moderate to strong correlations exist between UE accelerometry and 
electromyography during activities of daily living (r = 0.53) 104, elbow electrogoniometry during daily use (r = 0.94) 105, 
and standardized measures that assess impairment, function, and activity (see Table 3).  Low correlations between UE 
accelerometry and the mobility subscale of the Stroke Impact Scale (r = 0.16 - 0.23) indicate that UE accelerometry is 
not associated with lower extremity activity  106, thereby demonstrating divergent validity.  
The utility of accelerometers for clinical practice 
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Accelerometers are relatively inexpensive ($100- 500 per unit), commercially-available, and complement 
information gained from other available measures.  Accelerometers can be used to measure UE use during the initial 
evaluation, weekly or monthly during the course of treatment, and at discharge.  UE use can then be compared across 
time points to assess change in use.  When used this way, UE use as measured by accelerometry, is an intuitive 
measure of recovery and return to daily activity and participation.  The counts or amount of use generated by 
accelerometers can be appreciated by the person receiving therapy services, his/her family members, other clinicians, 
and third-party payers.  It is relatively simple for persons receiving rehabilitation services to understand his/her UE 
recovery as measured by an increase in hours of UE use in a day.  These numbers are more intuitive than changes of 
one or a few points on clinical rating scales.  Direct measures of use may also motivate the individual and the family to 
continue efforts to incorporate gains made in therapy into everyday life.  Additionally, rehabilitation clinicians will 
benefit from tracking change in UE use during treatment as a means of evaluating the effectiveness of the chosen 
interventions.  If an intervention has increased the real-world use of the affected UE, these numbers are proof of the 
benefit.  If an intervention has failed to increase the real-world use of the affected UE, then a different approach needs 
to be selected or therapy services need to be terminated.  A quantitative measure showing increased UE use during 
the course of therapy services can be submitted with other documentation when requesting additional therapy 
services from a third-party payer.  Our laboratory is in the process of collecting normative data with accelerometers; 
these values will be useful benchmarks for assessing the extent of improvement in individual patients.    
  While accelerometers provide useful information, some limitations deserve consideration.  Accelerometers 
are electronic devices that are subject to mechanical failure and need to be checked at regular intervals.  Another 
limitation is that accelerometer data has to be processed by a software program.  Care must be exercised when 
choosing accelerometers and software programs to ensure that the user will be able to adjust program settings in 
order to report activity counts in terms of UE use.  Fortunately, current available software has become substantially 
more user-friendly over the past 10 years, even for busy clinicians.  Finally, compliance with wearing the 
accelerometers may be an issue for some individuals when wearing them for a long period of time, forgetting to 
replace accelerometers after removal for showering or hand washing, or cognitive deficits.    Despite their limitations, 
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accelerometers are practical and useful devices that allow a clinician to collect valuable, objective information that 
would be otherwise unavailable.  They allow UE use to be measured outside of a clinical setting and to effectively 
measure rehabilitation outcomes in the real world.  
 
USING ASSESSMENT RESULTS TO MAKE CLINICAL DECISIONS  
Results derived from both impairment and functional assessments assist the clinician with the development of 
treatment plans and aid with evaluating the utility of a particular treatment.  In addition to assessment results, clinical 
decisions depend on the prognosis for recovery of impairments and function after stroke.  Epidemiological data from 
multiple countries show that recovery after stroke occurs along a fairly predictable time course.  Most motor and 
functional recovery will occur within the first 3 months 107, 108.  Early severity of paresis is the best predictor of eventual 
motor deficits and function 39, 109, 110.  Those with mild deficits recover more quickly and completely, with best 
neurological recovery occurring within 3 – 6 weeks 108.  Those with more severe deficits recover more slowly and to a 
much lesser extent, with best neurological recovery occurring within 13 – 15 weeks 108.  For the purpose of predicting 
recovery of individual patients, the epidemiologic data provide the general pattern of recovery and most, but not all, 
patients will follow a similar time course of changes.  There are three additional indicators of future outcomes that are 
useful to look for when trying to determine prognosis in individuals. First, the more non-motor impairments (e.g., 
somatosensory loss or visual field loss) that accompany the motor deficits (e.g., paresis, fractionated movement 
deficit), the less likely a person is to return to functional independence 111.  Second, early, rapid improvements in 
motor impairments are an indication that a person is more likely to reach higher levels of independence 108, 112.  And 
third, the absence of measurable grip strength or shoulder flexion at 3-4 weeks post stroke is a strong indicator that 
the affected upper limb will be non-functional 25, 29, 110, 113.  Recovery of function typically lags recovery of neurological 
impairments by about 1 to 2 weeks, with the trajectory of the two recovery curves being nearly identical 108.  The 
reason for the 1 – 2 week lag may be that as impairments improve, practice is required to capitalize on the 
neurological recovery and incorporate the improvements into daily function. 
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The combination of the individual’s assessment data, the time since their stroke, and the epidemiological data 
reviewed above will allow the clinician to determine: 1) whether or not more neurological recovery is expected; and 2) 
whether or not more functional recovery is expected.  For many individuals with stroke, motor and somatosensory 
impairments will not substantially change, but activity limitations and participation restrictions can be lessened 
through a course of rehabilitation.  For example, a person that is 2 years post stroke with a Motricity Index of 27 (MMT 
grades of 2/5 in the three candidate motions) and absent light touch sensation on the palm on their affected UE would 
be expected to have no or minimal changes at the impairment level.  It is highly possible however, that a course of 
rehabilitation therapy with a focus on functional training for the individual and his/her family, may improve daily 
activities such as bathing and dressing and may reduce caregiver assistance needed with these activities.  Determining 
expectations about the likelihood of neurological and functional recovery from assessment scores will facilitate: 1) 
setting realistic treatment goals; and 2) selecting a restorative or compensatory approach to achieve those goals. 
Choosing a restorative or a compensatory approach is critical when developing the plan of care for an 
individual with stroke.  A restorative approach is focused on returning or restoring the previously lost motor abilities 
and function.  A compensatory approach is focused on maximizing function, often with alternate strategies, within the 
confines of the limited motor abilities.  In managing the UE post stroke, a restorative approach would be chosen if the 
person had a stroke less than 3 months earlier and assessment results indicate there is voluntary, fractionated 
movement against gravity at several UE segments 114.  In contrast, a compensatory approach would be chosen for a 
person with minimal or no voluntary, fractionated movement, whether early or later poststroke 114.   The expectation 
for the restorative approach is that a course of rehabilitation will return the arm and hand to a reasonable, functional 
level of dexterity. The expectation for the compensatory approach is that a course of rehabilitation will educate the 
individual to minimize contracture development, edema, and potential hygiene problems, and possibly permit the arm 
and hand to be used as an assist during functional activities.  In the neurological therapy world, there is an often-
voiced concern that the decision to use a compensatory approach will limit a person’s eventual recovery.  There is 
limited empirical data to support this concern.  In fact, results from the VECTORS trial, a Phase II trial evaluating 
constraint induced movement therapy in the inpatient rehabilitation setting, suggest otherwise 115.  In this study, the 
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experimental group received focused training aimed at restoring normal movement of the affected limb while the 
control group received general training and could not be cued to use their affected limb or told to use it in a specific 
way.  UE function improved to a similar degree in these two dose-matched groups, and scores were equivalent at the 
end of the intervention and at 3 months post stroke.  An equal but less discussed concern is that the decision to use a 
restorative approach could waste valuable therapy time, leaving a person with stroke ill-equipped to function in daily 
life once the course of therapy is completed.  There is no easy answer to these competing concerns.  Frequent re-
assessment of key impairments and activity limitations will enable the clinician to determine if the appropriate 
approach was chosen and if a switch to the alternate approach is needed. 
Specific interventions are chosen once the approach has been determined. Interventions for the UE post-
stroke are generally targeted toward improving function and not targeted at improving impairments in isolation 114, 116.  
The challenge to the clinician lies in selecting and structuring functional training to address the movement dysfunction 
(restorative and compensatory approaches) and underlying impairments (restorative approach only).  For example, if 
the individual’s goal is to return to gardening activities, then therapy sessions and the home exercise program would 
be used to practice (or simulate practice of) various aspects of gardening such as grasping and using tools, digging, and 
moving plants.  If the approach is compensation, then the specific treatment will focus on executing gardening 
activities safely with whatever positions (seated vs. standing), motions (primarily use unaffected hand), and assistive 
devices (adaptive tools) are appropriate. If the approach is restorative, then the specific treatment will focus on 
returning normal movement patterns while grasping and using gardening tools.  While further discussion of specific 
interventions and their evidence of benefit is beyond the scope of this chapter, the reader is encouraged to access 
excellent online summaries such as the Evidence-Based Review of Stroke Rehabilitation114 (www.ebrsr.com) and the 
StrokeEngine (www.strokengine.ca ).     
Repeated administration of one or several measures is of great benefit to persons receiving stroke 
rehabilitation and clinicians managing their rehabilitation course.  For the person with stroke, an improved score (e.g. 6 
kg of grip force now compared to 3 kg two weeks ago, 41/57 on the ARAT now compared to 21/57 two weeks ago) can 
motivate them to continue with their long, demanding course of rehabilitation.  If the scores are not improving, this 
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information can affirm that their perception of stalled performance may be accurate.  For the clinician, it is an 
objective, quantitative method to assess progress.  Data from the measures address issues of whether or not a person 
is continuing to improve, whether or not the selected intervention is improving impairments and function as hoped, 
and whether or not continued therapy services are warranted.  Clinicians will want to select a reasonable interval for 
re-assessment, i.e. a time in which improvements would be expected to occur.  In short inpatient stays, now averaging 
16-17 days in the United States 117, 118, formal re-assessment of UE impairments and activity restrictions may take place 
in the days before discharge.  These results would then be used to educate the person with stroke and his/her family, 
to select appropriately graded home activities and exercises, and to provide information to the next point of care.  For 
outpatient services, re-assessment might be most appropriate on a monthly basis, as changes in impairment and 
function will be occurring more slowly than they were immediately after stroke and visits will be one or a few times 
per week.  Reassessment of functional improvement is the key factor in keeping the person, family, and physician 
updated on rehabilitation progress. 
 
SUMMARY 
The purpose of this review was to provide a comprehensive approach for assessing the UE after stroke.  
Evaluating the presence and severity of UE impairments and function after stroke is critical for understanding not only 
how well the UE is used in the clinic, but also how much the limb may be used during activities of daily living at home 
or work. Many of the assessments provided in this review are reliable and valid, with high levels of consistency 
(between raters and post-stroke time points) and correlation (between the assessments themselves).  While knowing 
what constructs are being tested by each assessment is important, knowing how these assessments provide insight 
into the larger picture of UE function and recovery is useful in formulating goals and treatment plans for individuals 
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Table 1. Assessment of common upper extremity impairments after stroke 
Impairment Assessment Time to 
administer 
Description Reliability Details 
Paresis Motricity Index 
119, 120 
3 min Manual Muscle Test Score is 
given for shoulder abduction, 
elbow flexion and pinch grip. 
Together these scores are 
converted to a total force 
production score for each UE 
ranging from 0 (no strength) to 




Paresis after stroke similarly 
affects movement at each 
segment. This means that 
one needs to test only a UE 
few segments.  The 
Motricity Index is quick and 
provides a total force score 
for the entire UE. 
Grip Strength  
Pinch Strength 
121, 122 
2-3 min Hand-Held Dynamometer to 
assess kilograms or pounds of 
force.  Age- and gender-




Measurement of handgrip 
strength has been shown to 
predict motor performance 
and functional 










during paresis  
assessment; 
5-6 min  
Presence or absence of 
movement fractionation 
observed; note any 
substitutions or associated 
reactions 
N/A As part of the paresis 
assessment, fractionation of 
movement can be assessed. 
Muscle Tone Modified 
Ashworth Scale 
31 
< 5 min Six point scale from 0 (no 
increase in muscle tone) to 4 




The elbow flexors are most 
easily and commonly 
assessed in the UE. 
Somatosen 
-sation 
Light Touch 1-2 min Light touch sensation can be 
noted as Intact, Impaired (i.e. 
less feeling compared to other 
side), or Absent based on one 
light stroke to the skin of the 
UE 
N/A Loss of somatosensation 
after stroke typically occurs 
across multiple modalities 
and across the entire limb. 
Light touch is the most 
common modality assessed.  
Results from a single, 
representative modality at 
1-2 sites are an indicator 
that similar deficits exist in 
other modalities and at 





Section 123 84  
30 min The upper limb section has 33 
items including: movement 
observation, reflex testing, 
grasp testing and coordination. 
Three point scale from 0 
(unable to perform) to 2 (able 
to perform) totaling 66 for the 
upper limb portion. 
Intrarater ICC= 0.99 
Interrater ICC=0.96 
The Fugl-Meyer provides a 
global assessment of UE 
impairment. Often a quicker 
measure of paresis is 
selected over the Fugl-








Table 2. Performance and self-report measures commonly used to assess upper extremity function after stroke 
Performance Assessments 
Name Time to 
administer  
Reliability Relation to other 
measures (Concurrent 
Validity) 
Estimate of MCID* Strengths Weaknesses 
Action Research 
Arm Test 
10-15 min Intrarater r=0.99 
Interrater r=0.98 
Test-retest r=0.98 
r=0.91-.94 with  Fugl-
Meyer;  
r=0.96 with Motor 
Assessment Scale ; 
r=0.87 with Motricity 
Index;  
r = 0.93 with CAHAI 
6 pts (chronic 
stroke); 
12 points (acute 
stroke - dominant 
hand); 






Appropriate at all 
stages of recovery 
Not commercially-
available, but can 
be built from 
published 
instructions 
Box & Blocks 
Test (BB) 
5-10 min Intrarater ICC= no 
established studies 
Interrater ICC= 0.99 
Test-retest ICC= 0.96 
r=0.92 with Fugl-
Meyer;  
r=0.95 with ARAT 













25 min Intrarater ICC= no 
established studies 
Interrater ICC= 0.98 
Test-retest ICC= 0.96 - 
.97 
r = 0.93 with ARAT  6.3 points Easily 
administered; 
Shorter versions of 
the test exist if 
time is a concern; 
Free to use 
Takes longer than 
other measures 





15-20 min Interrater ICC= 0.82-
1.00 
 
rs= 0.84-.97 with 9-
Hole Peg Test; 
rs= 0.87-.95 with ARAT 
unknown Standardized 
instructions; good 
measure when the 
ceiling is achieved 
on other shorter 
measures 
Requires at least 





10 min Interrater/Test-retest: 
r= 0.68-.99 
rs= 0.84-.97 with 
Jebsen-Taylor 
rs= 0.85-.93 with ARAT 














rs= 0.86 (FAS) with 
ARAT 




1.5-2 sec (WMFT 
time -  chronic 
stroke);  







Appropriate at all 
stages of recovery 
Takes longer than 
other measures 
that capture the 
same information 








rs=0 .35-.39 (QOM 
scale) with ARAT 
rs= 0.31-.32 (AOU 
scale) with ARAT 
rs= -0.26- -.33 (QOM 
scale) with 9-Hole Peg 
Test 
rs= -0.16- -.23 (AOU 
scale) with 9-Hole Peg 
Test 
rs= -0.52 (QOM scale) 
with BB 
rs= -0.37-.49 (AOU 








Tries to capture 
real-world 
abilities; Easy to 
administer 














rs= 0.57-.73 with ARAT 
rs= 0.61-.83 with 
Jebsen-Taylor 
rs= 0.53-.66  with 9-
Hole Peg Test 
ADL/IADL = 5.9 pts 




to capture  real-
world abilities;  
Easy to administer 
Relies on self-
ratings 
*Minimal Clinically Important Difference (MCID) has been defined as “the smallest difference in score in the domain of interest which patients perceive as 
beneficial and which would mandate, in the absence of troublesome side effects and excessive cost, a change in the patient’s management” 125.  Note that these 
values are labeled as estimates because they are likely influenced by the time post-stroke and the severity of functional loss.  
23 
 
Table 3.   Relationships between accelerometry measures of upper extremity use and impairment, self-report, and performance 
measures.  Note that some of the performance measures specifically assess the upper extremity while others assess additional 
constructs, such as mobility and activities of daily living.     
 CORRELATION 
IMPAIRMENT MEASURES  
Motricity Index   r=0.5*  102  
Fugl-Meyer Assessment—Arm 
Section  
r =-0.851** 126 
r=0.54** 127 
  
PERFORMANCE MEASURES  
Action Research Arm Test   r=0.40†  99 
Wolf Motor Function Test  r=0.62* 99 
Functional Impairment Measure  r=0.67,* 99 
Barthel Index  ρ=0.64* 102 
  
SELF-REPORT MEASURES  
Stroke Impact Scale – Hand Function 
subscale  
r=0.61** 103 
Motor Activity Log – Quality Of 
Movement scale  
r=0.52**  98 
r=0.66** 103 





Figure 1.  Schematic representation of data from multiple studies in our lab 24, 25, 30, 36-38.  In each panel, the large, white circles 
represent the construct of UE function.  The size of the smaller, filled circles represent how much the impairment (A & C, paresis) 
or joint (B) contributes to UE function.  A: At nearly all time points post stroke, the severity of paresis can explain the majority of 
variance in UE function.  B: Loss of UE function stems from paresis across the limb, and not paresis at just a few joints.  C: Paresis a 
few weeks, but not a few days after stroke can predict later UE function.  Other impairments tested included muscle tone, 
fractionation of movement, and somatosensory loss.  These other impairments did not add any additional contributions to UE 










Figure 2.  Accelerometry can be a useful tool to measure UE use outside of the clinic or laboratory.  A: Picture of commercially-
available accelerometers worn on the wrists (GT3X+ Activity Monitor, ActiGraph, Pensacola FL).  The size of each accelerometer is 
4.6 cm x 3.3 cm x 1.5 cm.  B: An example of what UE accelerometer data looks like.  The date of the recording is provided at the 
top, and data is shown from 2:30 pm to 4:00 pm.  The data line indicates the count or how much the limb was moving during this 
1.5 hour period.  Moments when the line is equal to zero indicate times when the limb was not moving.     
